Skip to content
value.today

Imago BioSciences, Inc.

Total raised
$138 M
3 rounds on record
Latest round
$80 M
Nov 2020
First round on record
Oct 2014
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Imago BioSciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2020$80 MNo. 3$50 to $250 million

Imago BioSciences, Inc.: Raise no. 3, Nov 2020

Investors in this round

28 investors had bought by the notice of Nov 20, 2020: 28 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Imago BioSciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$80 M of $80 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Hugh Y. Rienhoff, Jr. · Executive Officer, Director
  • Laura G. Eichorn · Executive Officer
  • Dennis J. Henner · Director
  • Dina Chaya Moghrabi · Director
  • Harish Chaya Soundararajan · Director
  • Patrick J. Heron · Director
  • Robert Chaya Baltera · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Laura G. Eichorn, Chief Operating Officer. Source: SEC Form D, newest notice filed Nov 20, 2020. Read the notice at the SEC.

equitySEC
Mar 2019$17 MNo. 2$10 to $50 million

Imago BioSciences, Inc.: Raise no. 2, Mar 2019

Investors in this round

12 investors had bought by the notice of Mar 28, 2019: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Imago BioSciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$17 M of $40 M offered; $23 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Hugh Y. Rienhoff, Jr. · Executive Officer, Director
  • Laura G. Eichorn · Executive Officer
  • Alan Chaya Sachs · Director
  • Dennis` J. Henner · Director
  • Dina Chaya Moghrabi · Director
  • Patrick J. Heron · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Benjamin A. Potter, Secretary. Source: SEC Form D, newest notice filed Mar 28, 2019. Read the notice at the SEC.

equitySEC
Oct 2014$41 MNo. 1$10 to $50 million

Imago BioSciences, Inc.: Raise no. 1, Oct 2014

Investors in this round

7 investors had bought by the notice of Feb 22, 2017: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Imago BioSciences, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$41 M of $41 M offered
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$2,242,956 (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Hugh Y. Rienhoff · Executive Officer, Director
  • Laura G. Eichorn · Executive Officer
  • Alan G. Sachs · Director
  • Dennis G. Henner · Director
  • Patrick G. Heron · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Benjamin A. Potter, Secretary. Source: SEC Form D and 1 amendment, newest notice filed Feb 22, 2017. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Imago BioSciences, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2020).

    SEC Form D · Nov 2020

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Nov 2020

That is all the official record says: Imago BioSciences, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

14 named in official filings. Open an investor to see everything it has backed.

Investors in Imago BioSciences, Inc.
InvestorKindAmountRoundRoleSource
Blackstone Clarus III L.L.C.Othernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Blackstone Group Management L.L.C.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Blackstone Holdings I/II GP IncCompanynot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Blackstone Holdings II L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Blackstone Inc.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Clarus Lifesciences III, L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Clarus Ventures III GP, L.P.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
FHM VII, L.L.C.Othernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
FHM VII, L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Frazier Healthcare VII-A, L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Frazier Healthcare VII, L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Omega Fund VI GP, L.P.Fund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Omega Fund VI GP Manager, Ltd.Fund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Omega Fund VI, L.P.Fund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2021)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 28 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Imago BioSciences, Inc.
NameRoleNamed in
Hugh Y. Rienhoff, Jr.Executive officerNov 2020
Laura G. EichornExecutive officerNov 2020
Hugh Y. RienhoffExecutive officerFeb 2017
Dennis J. HennerDirectorNov 2020
Dina Chaya MoghrabiDirectorNov 2020
Harish Chaya SoundararajanDirectorNov 2020
Hugh Y. Rienhoff, Jr.DirectorNov 2020
Patrick J. HeronDirectorNov 2020
Robert Chaya BalteraDirectorNov 2020
Alan Chaya SachsDirectorMar 2019
Dennis` J. HennerDirectorMar 2019
Alan G. SachsDirectorFeb 2017
Dennis G. HennerDirectorFeb 2017
Hugh Y. RienhoffDirectorFeb 2017
Patrick G. HeronDirectorFeb 2017